Reach Us +1-947-333-4405
Human-on-a-chip Systems To Direct Or Possible Augment Clinical Trials | 30845
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Human-on-a-chip systems to direct or possible augment clinical trials

International Conference on Clinical Trials

James J Hickman

ScientificTracks Abstracts-Workshop: J Clin Trials

DOI: 10.4172/2167-0870.S1.007


One of the primary limitations in drug discovery and toxicology research is the lack of good model systems between the single
cell level and animal or human systems. This is especially true for neurodegenerative diseases as well as for cardiac disease and
cardiac side effect determination during the drug discovery process. In addition, with the banning of animals for toxicology testing
in many industries, body-on-a-chip systems to replace animals with human mimics is essential for product development and safety
testing. There is also a push to utilize in vitro systems to establish biomarkers to select subsets of the population for clinical trials and
even to augment human testing during clinical trials. Our research focus is on the establishment of functional in vitro systems to
address this need where we seek to create organs and subsystems to model motor control and cognitive function, as well as cardiac
and liver subsystems. The idea is to then integrate microsystems fabrication technology and cellular components, with the aim of
initiating and maintaining self-assembly and growth into biologically, mechanically and electronically interactive functional multicomponent
systems. Our advances in culturing human stem cell derived neurons, glial cells, muscle, liver and cardiomyocytes in a
defined serum-free medium, and integrate them with MEMS devices suggest outstanding potential for answering questions during
all phases of the drug discovery process using functional body-on-a-chip systems.


James J Hickman is the Founding Director of the NanoScience Technology Center and a Professor of Nanoscience Technology, Chemistry, Biomolecular Science,
Physics, Material Science and Electrical Engineering at the University of Central Florida. Previously, he held the position of the Hunter Endowed Chair in the
Bioengineering Department at Clemson University. He has a PhD from the Massachusetts Institute of Technology in Chemistry, as well as BS and MS from Penn
State University in Chemistry. For the past twenty-five years, he has been studying the interaction of biological species with modified surfaces, first in industry
and in the latter years in academia. While in industry he established one of the first bioelectronics labs in the country that focused on cell-based sensors and their
integration with electronic devices. He has extensive experience in surface modification and surface analysis for biological and neuroscience applications, and
the integration of these systems with MEMS devices and components for human body-on-a-chip applications. He is also the Founder and current Chief Scientist
of a biotechnology company, Hesperos that is focusing on cell-based systems for drug discovery and toxicity. He has 110 publications and 18 book chapters, in
addition to 26 patents.